Schroder Investment Management Group maintained its stake in Flexion Therapeutics Inc. (NASDAQ:FLXN) during the second quarter, Holdings Channel reports. The fund owned 331,530 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. Schroder Investment Management Group owned approximately 1.20% of Flexion Therapeutics worth $4,961,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Amici Capital LLC acquired a new position in shares of Flexion Therapeutics during the first quarter worth about $184,000. A.R.T. Advisors LLC purchased a new stake in Flexion Therapeutics during the first quarter worth $188,000. Bank of Montreal Can purchased a new stake in Flexion Therapeutics during the second quarter worth $204,000. Commonwealth Equity Services Inc purchased a new stake in Flexion Therapeutics during the second quarter worth $251,000. Finally, Royal Bank of Canada boosted its stake in Flexion Therapeutics by 5.7% in the first quarter. Royal Bank of Canada now owns 28,893 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 1,566 shares in the last quarter. 68.27% of the stock is owned by hedge funds and other institutional investors.

Flexion Therapeutics Inc. (NASDAQ:FLXN) traded up 1.85% during midday trading on Tuesday, hitting $17.07. The stock had a trading volume of 54,497 shares. Flexion Therapeutics Inc. has a one year low of $7.56 and a one year high of $25.88. The stock’s market cap is $469.78 million. The firm has a 50 day moving average price of $17.04 and a 200 day moving average price of $13.74.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Wednesday, August 3rd. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.04. Equities analysts expect that Flexion Therapeutics Inc. will post ($2.69) EPS for the current year.

A number of research firms recently weighed in on FLXN. Janney Montgomery Scott restated a “buy” rating and issued a $30.00 price target on shares of Flexion Therapeutics in a report on Friday, July 1st. BMO Capital Markets began coverage on Flexion Therapeutics in a report on Tuesday, June 28th. They issued an “outperform” rating and a $35.00 price target on the stock. Cantor Fitzgerald restated a “buy” rating on shares of Flexion Therapeutics in a report on Thursday, May 26th. Vetr upgraded Flexion Therapeutics from a “buy” rating to a “strong-buy” rating and set a $15.50 price target on the stock in a report on Monday, June 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $34.00 price target (up previously from $28.00) on shares of Flexion Therapeutics in a report on Friday, May 27th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Flexion Therapeutics presently has an average rating of “Buy” and a consensus target price of $32.31.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

5 Day Chart for NASDAQ:FLXN

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc. (NASDAQ:FLXN).

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.